X4 Pharmaceuticals, Inc: insider trades · United States · SEC (Form 4)

About X4 Pharmaceuticals, Inc

X4 Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company listed on the Nasdaq (XFOR) in the United States, focused on developing and commercializing innovative therapies for rare immune-system and hematology disorders linked to CXCR4 biology. The company is headquartered in Boston, Massachusetts. Its roots go back to a CXCR4-focused scientific platform and a licensing foundation with Sanofi/Genzyme, and the modern company was shaped through the merger with Arsanis and a subsequent refocusing on high-unmet-need rare disease programs. X4 was founded in 2014. ([investors.x4pharma.com](https://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-completes-merger-arsanis/?utm_source=openai)) X4’s lead asset is mavorixafor, an oral selective CXCR4 antagonist. The drug is marketed in the United States as XOLREMDI® for WHIM syndrome, a rare primary immunodeficiency. That makes X4 more than a pure clinical-stage story: it has moved into a partially commercial biopharma model, although the company’s value remains heavily concentrated in a single lead asset. Management also states that it is running the pivotal Phase 3 4WARD trial in chronic neutropenic disorders, supported by FDA Fast Track designation for mavorixafor in chronic neutropenia. ([investors.x4pharma.com](https://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-reports-fourth-quarter-and-full-year-2025?utm_source=openai)) From a competitive standpoint, X4 is a specialist rather than a broad-platform pharma company. Its differentiation comes from CXCR4 biology and its focus on rare diseases with limited treatment options, which can support meaningful clinical and commercial exclusivity if development succeeds. At the same time, this concentration creates high execution risk: the investment case depends disproportionately on regulatory milestones, adoption of XOLREMDI, and the outcome of the company’s key clinical program. X4 previously explored additional CXCR4 programs, including oncology and preclinical initiatives, but it has narrowed its focus to maximize value around its core asset. ([investors.x4pharma.com](https://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-announces-strategic-restructuring-drive-value?utm_source=openai)) Recent developments underscore that strategy. In its first-quarter 2026 update, X4 said its top priority remains execution and full enrollment of the pivotal 4WARD study, and it noted that net product sales were primarily driven by U.S. sales of XOLREMDI. In early 2026, the company also reported full-year 2025 results and a corporate update, reinforcing that the story is centered on rare hematology and continued development progress. For French-speaking investors, X4 should be viewed as a specialty small-cap biotech on the Nasdaq in the United States, with a concentrated pipeline, a commercial foothold in a rare disease, and a valuation that will likely remain highly sensitive to clinical, regulatory, and launch execution milestones. ([investors.x4pharma.com](https://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-reports-first-quarter-2026-financial-results?utm_source=openai))